Singapore Transdermal Adhesive Market Size & Outlook, 2025-2033
Singapore Transdermal Adhesive Market Insights
- According to Reed Intelligence analysis, the Singapore Transdermal Adhesive Market size was USD 23.87 Million in 2024 and is projected to reach USD 36.73 Million by 2033.
- The Singapore market is projected to grow at a CAGR of 4.91% between 2026 and 2033.
- By segment, Pain Management emerged as the largest Application in terms of market size in 2024.
- Cardiovascular Conditions is anticipated to remain the most attractive Application segment, recording the fastest growth during the forecast period.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2024, Singapore represented 0.33% of the overall global Transdermal Adhesive Market size.
- United States is projected to lead the global Transdermal Adhesive Market size by 2033.
- Across Asia Pacific, China is anticipated to hold the dominant position in market size by 2033.
- India is forecasted to expand at the fastest pace in Asia Pacific, attaining USD 312.67 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 23.87 Million |
| Market Size In 2033 | USD 36.73 Million |
| Largest segment | Pain Management |
| Units | Revenue in USD Million |
| CAGR | 4.91% (2025-2033) |
| Segmnetation Covered | |
| Application |
|
| Type |
|
| End Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Singapore Transdermal Adhesive Market Application 2025-2033 (USD Million)
| Application | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pain Management | XX.x | XX.x | XX.x | 8.52 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Hormonal Therapy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Smoking Cessation | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Cardiovascular Conditions | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Neurological Disorders | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Singapore Transdermal Adhesive Market Type 2025-2033 (USD Million)
| Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Microneedle Patches | XX.x | XX.x | XX.x | 9.77 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Reservoir Systems | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Matrix Systems | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Transdermal Films | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Singapore Transdermal Adhesive Market End Use 2025-2033 (USD Million)
| End Use | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 11.21 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Pharmacies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Homecare | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Research Laboratories | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
